Wall Street brokerages predict that Clovis Oncology (NASDAQ:CLVS) will post ($1.35) earnings per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Clovis Oncology’s earnings, with the highest EPS estimate coming in at ($1.11) and the lowest estimate coming in at ($1.53). Clovis Oncology posted earnings of ($1.13) per share in the same quarter last year, which indicates a negative year over year growth rate of 19.5%. The firm is expected to announce its next earnings report on Wednesday, May 2nd.
On average, analysts expect that Clovis Oncology will report full year earnings of ($4.81) per share for the current fiscal year, with EPS estimates ranging from ($5.87) to ($2.82). For the next year, analysts anticipate that the company will report earnings of ($1.88) per share, with EPS estimates ranging from ($4.67) to $0.31. Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Clovis Oncology.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.29) by $0.25. The business had revenue of $17.04 million during the quarter, compared to analysts’ expectations of $19.42 million. Clovis Oncology had a negative return on equity of 81.34% and a negative net margin of 624.02%. The firm’s quarterly revenue was up 21746.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.83) earnings per share.
A number of analysts have commented on the company. Zacks Investment Research raised Clovis Oncology from a “sell” rating to a “hold” rating in a report on Thursday. BidaskClub lowered Clovis Oncology from a “hold” rating to a “sell” rating in a report on Thursday. ValuEngine lowered Clovis Oncology from a “hold” rating to a “sell” rating in a report on Tuesday. Bank of America reduced their target price on Clovis Oncology from $90.00 to $55.52 and set a “buy” rating for the company in a report on Monday, April 9th. Finally, SunTrust Banks lifted their target price on Clovis Oncology to $90.00 and gave the stock a “buy” rating in a report on Monday, April 9th. Two analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $87.60.
In related news, Director Thorlef Spickschen sold 4,500 shares of Clovis Oncology stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $60.00, for a total value of $270,000.00. Following the completion of the sale, the director now owns 16,618 shares of the company’s stock, valued at $997,080. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $54.09, for a total value of $162,270.00. Following the completion of the sale, the insider now directly owns 180,571 shares of the company’s stock, valued at approximately $9,767,085.39. The disclosure for this sale can be found here. Insiders sold 16,500 shares of company stock valued at $978,975 in the last ninety days. 12.50% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Palo Alto Investors LLC grew its holdings in shares of Clovis Oncology by 2.2% in the fourth quarter. Palo Alto Investors LLC now owns 3,402,781 shares of the biopharmaceutical company’s stock worth $231,389,000 after acquiring an additional 73,200 shares during the period. Franklin Resources Inc. grew its holdings in Clovis Oncology by 13.8% during the fourth quarter. Franklin Resources Inc. now owns 2,634,401 shares of the biopharmaceutical company’s stock valued at $179,138,000 after purchasing an additional 318,931 shares during the period. Redmile Group LLC grew its holdings in Clovis Oncology by 32.5% during the fourth quarter. Redmile Group LLC now owns 1,320,027 shares of the biopharmaceutical company’s stock valued at $89,762,000 after purchasing an additional 323,417 shares during the period. Alliancebernstein L.P. grew its holdings in Clovis Oncology by 4.3% during the fourth quarter. Alliancebernstein L.P. now owns 1,002,897 shares of the biopharmaceutical company’s stock valued at $68,197,000 after purchasing an additional 41,120 shares during the period. Finally, HealthCor Management L.P. grew its holdings in Clovis Oncology by 50.4% during the fourth quarter. HealthCor Management L.P. now owns 973,840 shares of the biopharmaceutical company’s stock valued at $66,221,000 after purchasing an additional 326,420 shares during the period.
Shares of Clovis Oncology stock traded down $2.80 on Thursday, reaching $51.32. The company’s stock had a trading volume of 1,682,775 shares, compared to its average volume of 1,347,242. The firm has a market cap of $2,791.51, a price-to-earnings ratio of -10.02 and a beta of 0.93. Clovis Oncology has a 52 week low of $45.42 and a 52 week high of $99.45. The company has a current ratio of 7.69, a quick ratio of 7.35 and a debt-to-equity ratio of 0.77.
COPYRIGHT VIOLATION WARNING: “Clovis Oncology (CLVS) Expected to Post Earnings of -$1.35 Per Share” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.thelincolnianonline.com/2018/04/20/clovis-oncology-clvs-expected-to-post-earnings-of-1-35-per-share.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.